Date: June 28, 2013
Time: 8:30 a.m. to 12:30 p.m.
Location: FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
On June 28, 2013, FDA is conducting a public meeting on lung cancer Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of lung cancer on daily life, (topic 1) and on currently available therapies to treat the condition (topic 2). The questions for discussion on these topics are below.
For each of these topics, a panel of patients and patient representatives/advocates will present comments to begin the dialogue and will be followed by a facilitated discussion inviting comments from other patients and patient representatives.
If you are interested in providing comments as part of the initial panel discussion, indicate so during the registration process. Participants for the panel discussions will be confirmed prior to the meeting.
There will also be an opportunity for patients, patient representatives and others to provide comments on issues other than topics 1 and 2 during an Open Public Comment session. Sign up for Open Public Comment will take place the day of the meeting.
For more information, refer to the FDA meeting website.
Questions for Discussion
Topic 1: Disease symptoms and daily impacts that matter most to patients
1) For context, how long ago was your diagnosis of lung cancer? Is your cancer currently in only one area of the lung or has it spread to other parts of the lung or outside of the lungs?
2) Of all the symptoms that you experience because of your lung cancer, which 1 to 3 symptoms have the most significant impact on your daily life? (Examples may include pain, cough, shortness of breath, fatigue, voice hoarseness.)
3) Are there specific activities that are important to you but that you cannot do at all, or as fully as you would like, because of lung cancer? (Examples may include sleeping through the night, climbing stairs, household activities.)
Topic 2: Patients’ perspectives on current approaches to treating lung cancer
1) Are you currently undergoing any cancer treatments to help reduce or control the spread of your lung cancer? Please describe.
a) What do you consider to be the most significant downsides of these treatments? (Examples of downsides may include side effects, going to the hospital for treatment, frequent blood tests, etc.)
b) How do these downsides affect your daily life?
2) What supportive care treatments, if any, are you taking to help improve or manage the symptoms you experience because of your lung cancer? Please include any prescription medicines, over-the-counter products, and other therapies including non-drug therapies (such as breathing techniques).
a) What specific symptoms do your treatments address?
b) How well do these treatments manage these symptoms?
c) Are there symptoms that your current treatment regimen does not address at all,
or does not treat as well as you would like?
3) When thinking about your overall goals for treatment, how do you weigh the importance of prolonging your life versus improving the symptoms you experience because of your lung cancer?
4) What factors do you take into account when making decisions about using treatments to help reduce or control the spread of your lung cancer? In particular:
a) What information on the potential benefits of these treatments factors most into your decision? (Examples of potential benefits from treatments may include shrinking the tumor, delaying the growth of the tumor, prolonging life, etc.)
b) How do you weigh the potential benefits of these treatments versus the common side effects of the treatments? (Common side effects could include nausea, loss of appetite fatigue, diarrhea, rash.)
c) How do you weigh potential benefits of these treatments versus the less common but serious risks associated with the treatments? (Examples of less common but serious risks are developing a hole in the stomach or intestine, liver failure, kidney failure, lung inflammation, blood clot, stroke, heart attack, serious infections, etc.)